WaveMan · Company
IDXG · Interpace Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IDXG Interpace Biosciences (IDXG) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001054102
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-17.5%
XBRL, annual
Net margin
63.5%
Conversions, 180 days
2
Codes C/M, not in net · $0 priced
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.1M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$38.7M
FY Dec 2024$46.9M
FY Dec 2023$40.4M
FY Dec 2022n/a
FY Dec 2021$41.3M
Jun 2026$9.1M
Mar 2026$9.0M
Dec 2025$9.2M
Sep 2025$8.8M
Jun 2025$9.2M
Mar 2025$11.5M
Dec 2024$12.3M
Sep 2024$12.3M
At each fiscal year end
Single quarter
Net margin, TTM
+67.7%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025+63.5%
FY Dec 2024+14.3%
FY Dec 2023+5.0%
FY Dec 2022n/a
FY Dec 2021-36.2%
Jun 2026+1.7%
Mar 2026+8.0%
Dec 2025+245.9%
Sep 2025+10.4%
Jun 2025-6.9%
Mar 2025+14.3%
Dec 2024+15.3%
Sep 2024+13.6%
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
History
FY Dec 2025n/a
FY Dec 2024$3.8M
FY Dec 2023$3.3M
FY Dec 2022-$8.0M
FY Dec 2021n/a
Jun 2026$41.0K
Mar 2026$142.0K
Dec 2025$2.1M
Sep 2025$1.8M
Jun 2025n/a
Mar 2025n/a
Dec 2024$1.1M
Sep 2024$1.6M
At each fiscal year end
Single quarter
Debt to equity
0.08x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
History
FY Dec 20250.08x
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 20260.08x
Mar 20260.08x
Dec 20250.08x
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
2.55x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
History
FY Dec 20253.34x
FY Dec 20242.66x
FY Dec 20232.17x
FY Dec 2022-4.16x
FY Dec 2021-16.77x
Jun 20262.55x
Mar 20262.79x
Dec 20253.34x
Sep 20252.79x
Jun 20252.89x
Mar 20253.40x
Dec 20242.66x
Sep 20242.63x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+222.2%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025+244.2%
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026+222.2%
Mar 2026+210.4%
Dec 2025+244.2%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+104.4%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025+101.2%
FY Dec 2024+48.0%
FY Dec 2023+13.7%
FY Dec 2022-80.7%
FY Dec 2021-35.5%
Jun 2026+104.4%
Mar 2026+98.8%
Dec 2025+101.2%
Sep 2025+29.1%
Jun 2025+36.1%
Mar 2025+57.4%
Dec 2024+48.0%
Sep 2024+42.0%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -522%, not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+24.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
History
FY Dec 2025+24.8%
FY Dec 2024+276.9%
FY Dec 2023+234.4%
FY Dec 2022-29.6%
FY Dec 2021n/a
Jun 2026+24.0%
Mar 2026+19.2%
Dec 2025+24.8%
Sep 2025+64.2%
Jun 2025+103.5%
Mar 2025+329.3%
Dec 2024+276.9%
Sep 2024+149.8%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
6.71x
close 2026-10-09 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
History
FY Dec 20251.60x
FY Dec 20246.74x
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 20261.83x
Mar 20262.55x
Dec 20251.60x
Sep 2025n/a
Jun 2025n/a
Mar 20253.13x
Dec 20246.74x
Sep 20241.34x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$164.4M
market value at close 2026-10-09 on 2026-07-31 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
History
FY Dec 2025$4.7M
FY Dec 2024$12.2M
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026$44.2M
Mar 2026$51.5M
Dec 2025$4.7M
Sep 2025$4.3M
Jun 2025$4.6M
Mar 2025$4.7M
Dec 2024$12.2M
Sep 2024$8.3M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.5%
TTM free cash flow over market value at close 2026-10-09
History
FY Dec 2025n/a
FY Dec 2024+31.7%
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026+9.1%
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025+126.0%
Mar 2025+121.8%
Dec 2024+31.7%
Sep 2024+46.9%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
History
FY Dec 20250.02x
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
Jun 2026n/a
Mar 20260.02x
Dec 20250.02x
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

IDXG Stock Sonar score 4/7 axes

Find similar shapesCompare

IDXG ranks highest on profitability (98th percentile) and financial health (83rd), and lowest on growth (11th), among Medical Devices peers.

Profitability
98
Inputs
  • Return on equity+222.2% · 99 pct, sector of 182
  • Return on assets+104.4% · 100 pct, sector of 213
  • Return on invested capitaleffective tax rate -522%, not meaningful
  • Return on capital employed+24.0% · 96 pct, sector of 188
Financial health
83
Inputs
  • Debt to equity0.08x · 72 pct, sector of 159
  • Cash flow to debt2.55x · 93 pct, sector of 150
Growth
11
Inputs
  • Revenue growth, YoY-17.5% · 11 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
81
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+8.3% · 62 pct, sector of 198
3 not measured: Insider conviction, Institutional and government, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-17.5% year over year
below 89% of Medical Devices
Margin
63.5% net margin
the highest in Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IDXG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+590.2%12M
-4%+258%+519%+781%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

Interpace Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for INTERPACE BIOSCIENCES, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns IDXG: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in IDXG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IDXG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Mr. Burnel
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$708.2K
$708.2K
$468.3K
+18%
n/a
2024
$703.8K
$703.8K
$434.5K
+160%
n/a
2023
$678.4K
$608.1K
$332.0K
+4%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122024-032023-12
Revenue$38.7M$46.9Mn/a$40.2M
Gross profit$24.1M$29.9Mn/a$25.1M
Operating income$4.1M$8.1Mn/a$4.0M
Net income$24.6M$6.7Mn/a$2.0M
EPS (diluted)0.890.40n/a0.45
Operating cash flow$5.8M$4.6Mn/a$3.8M
Cash$2.5M$1.5M$2.8M$3.5M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies